The Mayo Clinic Feels PEMF May Help Heart Disease
Post# of 8397
(Total Views: 444)
Posted On: 02/12/2023 10:51:37 PM
The Mayo Clinic Feels PEMF May Help Heart Disease
The Mayo Clinic is sponsoring a 120 patient Clinical Trial using a portable PEMF device on patients with myocardial ischemia, reduced blood flow to the heart due to blocked arteries.
"Pulsed electromagnetic field (PEMF) therapy is a noninvasive technique, which provides low field electromagnetic stimulation. The therapy of PEMF is achieved by altering biological and physiological systems via low energy and non-ionizing electromagnetic fields. PEMF therapy was originally used clinically to manage osteoarthritis related pain and stiffness and to augment bone healing. In addition, recent research has explored the beneficial therapeutic effect of PEMF on microvasculature and circulation. More recently, research interest has been toward the effect of PEMF on various targets, including peripheral vascular function and blood flow. It has been suggested that PEMF therapy enhances the binding of free calcium (Ca2+) to calmodulin (CaM) and this phenomenon might improve tissue repair and pain and moreover other studies suggested an effect of PEMF on Ca/CaM-dependent nitric oxide (NO) signaling pathway, which is one of the major components for controlling vascular tone and blood pressure (BP, figure 1). The investigators have recently demonstrated that in subjects with metabolic syndrome with hypertension, 12 weeks of daily therapy using Bioboosti tended to lower BP and raise plasma NO levels as well as improve flow mediated dilation. In a small pilot study from China, subjects with a history of diffuse coronary disease and evidence of myocardial ischemia performed radionuclide SPECT before and after PEMF therapy or control. In this small pilot study there was evidence of reduced ischemia in the treatment group vs a control group. Thus the focus of this proposal is to pursue a larger clinical trial to demonstrate the benefits of PEMF therapy using the Bioboosti PEMF device to reduce the ischemic burden in patients with coronary artery disease."
The BioBoosti PEMF device to be used in this Trial has been used by Chinese Healthcare Companies for several years allowing them to insure customers with heart disease if they commit to using the BioBoosti device on a regular basis.
This type of interest in PEMF by one of the most respected healthcare providers in the US is a major step forward in mainstreaming PEMF.
https://clinicaltrials.gov/ct2/show/NCT05111288
The Mayo Clinic is sponsoring a 120 patient Clinical Trial using a portable PEMF device on patients with myocardial ischemia, reduced blood flow to the heart due to blocked arteries.
"Pulsed electromagnetic field (PEMF) therapy is a noninvasive technique, which provides low field electromagnetic stimulation. The therapy of PEMF is achieved by altering biological and physiological systems via low energy and non-ionizing electromagnetic fields. PEMF therapy was originally used clinically to manage osteoarthritis related pain and stiffness and to augment bone healing. In addition, recent research has explored the beneficial therapeutic effect of PEMF on microvasculature and circulation. More recently, research interest has been toward the effect of PEMF on various targets, including peripheral vascular function and blood flow. It has been suggested that PEMF therapy enhances the binding of free calcium (Ca2+) to calmodulin (CaM) and this phenomenon might improve tissue repair and pain and moreover other studies suggested an effect of PEMF on Ca/CaM-dependent nitric oxide (NO) signaling pathway, which is one of the major components for controlling vascular tone and blood pressure (BP, figure 1). The investigators have recently demonstrated that in subjects with metabolic syndrome with hypertension, 12 weeks of daily therapy using Bioboosti tended to lower BP and raise plasma NO levels as well as improve flow mediated dilation. In a small pilot study from China, subjects with a history of diffuse coronary disease and evidence of myocardial ischemia performed radionuclide SPECT before and after PEMF therapy or control. In this small pilot study there was evidence of reduced ischemia in the treatment group vs a control group. Thus the focus of this proposal is to pursue a larger clinical trial to demonstrate the benefits of PEMF therapy using the Bioboosti PEMF device to reduce the ischemic burden in patients with coronary artery disease."
The BioBoosti PEMF device to be used in this Trial has been used by Chinese Healthcare Companies for several years allowing them to insure customers with heart disease if they commit to using the BioBoosti device on a regular basis.
This type of interest in PEMF by one of the most respected healthcare providers in the US is a major step forward in mainstreaming PEMF.
https://clinicaltrials.gov/ct2/show/NCT05111288
(3)
(0)